Technology Transfer: Moving a Validated Process Without Breaking It
A process validated at one site, or a method validated in one lab, means little the moment it moves somewhere else. Technology transfer is how that validated state survives the move.
01Why the series ends up here
A process validated at a development site, a cleaning limit calculated for one piece of equipment, an analytical method qualified in one laboratory — none of that automatically survives a move to a new site, a new team, or a scaled-up batch size. Technology transfer is the discipline that carries validated knowledge across that gap deliberately, rather than assuming it travels on its own.
WHO defines technology transfer as a logical, documented procedure that controls the transfer of a process, together with its documentation and professional expertise, between development and manufacture, or between manufacturing sites.1,2 The 2022 update to WHO's guidelines folded in the same ICH lifecycle thinking that runs through process validation, analytical method validation and quality risk management — the same threads this entire series has been pulling on.3,4
A sending unit (SU) — often R&D or an originating manufacturing site — and a receiving unit (RU) are both involved, and success is measured not just by documentation changing hands, but by the RU demonstrating it can actually reproduce the critical elements of the transferred process to everyone's satisfaction, including the applicable regulator's.1
Technology Transfer: Drug Product Manufacturing Process (AAPS Introductions in the Pharmaceutical Sciences)
A concise, current reference specifically on drug product manufacturing technology transfer, addressing the same ICH lifecycle alignment across FDA, EMA, WHO and PIC/S that shapes the framework covered below.
Find it on Amazon →02The regulatory foundations
| Framework | Issuing body | Core contribution |
|---|---|---|
| WHO Technical Report Series 961, Annex 7 (2011) | World Health Organization | Original WHO guidelines on transfer of technology in pharmaceutical manufacturing1,2 |
| WHO Technical Report Series 1044, Annex 4 (2022) | World Health Organization | Updated guidelines aligning technology transfer with the ICH Q8–Q12 lifecycle approach and adding due diligence/gap analysis3,4,5 |
| ICH Q10 & Q12 | International Council for Harmonisation | Pharmaceutical quality system and lifecycle management principles the WHO update explicitly incorporates4 |
The 2022 revision restructured the guidance around a clearer set of project phases and added an explicit due-diligence and gap-analysis step before planning even begins — a recognition that many transfer failures trace back to gaps identified too late, after the receiving unit was already committed to a timeline.4,5
03The technology transfer lifecycle
WHO's updated guidance organizes a transfer project into three phases.4,5 Click each to expand it.
Due diligence and gap analysis compare the sending unit's process, equipment, and quality system against the receiving unit's capabilities, surfacing differences — equipment scale, utilities, personnel experience — before any commitment is made.
- Gap analysis conducted before the receiving unit commits to a timeline
- Roles and responsibilities between SU and RU defined up front
A technology transfer protocol is developed defining what will be transferred, how success will be measured, and what qualification, validation and comparative testing will be required — drawing directly on the risk management principles covered earlier in this series.
- Critical process parameters, critical quality attributes and control strategy documented and shared
- Acceptance criteria for comparative/bridging studies agreed before execution
The process (production, packaging, cleaning) and analytical procedures are executed at the receiving unit, with results compared against the sending unit's historical performance and the protocol's predefined acceptance criteria.
- Production and QC method transfer both addressed, not just one or the other
- Results feed into a formal transfer report, closing the loop against Phase 1's gap analysis
Pharmaceutical Technology Transfer: A Multidimensional Learning Approach
Walks through the steps, documentation, and common failure factors of a transfer project end to end — a useful applied companion to the phase structure above.
Find it on Amazon →04Approaches to analytical method transfer
Moving a validated analytical method to a new lab doesn't have a single required approach — the strategy depends on risk and how much the method or matrix has changed. Switch tabs to compare the common options.
Comparative (side-by-side) testing. The most common approach: both the sending and receiving labs test the same samples using the same method, and results are compared against predefined statistical acceptance criteria — the scenario the calculator below is built around.
Co-validation. The receiving lab participates in the original method validation study itself, generating data at both sites simultaneously — useful when the method and receiving lab are both new.
Revalidation. The receiving lab performs a full or partial revalidation of the method, typically warranted when the transfer coincides with a significant method or matrix change rather than a simple site move.
Transfer waiver. No comparative testing is performed, justified by a documented risk assessment — appropriate only for low-risk methods (e.g., a simple, well-characterized compendial test) with strong existing evidence of robustness.
05Comparative testing acceptance calculator
For a side-by-side method transfer, one common acceptance approach compares the percent difference between the sending and receiving unit's mean results against a predefined limit. Enter results from both labs to see an illustrative comparison.
Method transfer mean comparison interactive
% Difference = |RU mean − SU mean| ÷ SU mean × 100. A commonly cited illustrative acceptance range for assay-type methods is within about 2% absolute difference, though the real limit must be defined in your protocol based on the method's own validated precision and the product's specification.
This is a simplified illustrative comparison, not a validated statistical acceptance test. A real comparative testing protocol should define acceptance criteria in advance (often via a two one-sided t-test, confidence interval approach, or method-specific precision data) and account for sample size — never rely on this tool alone to accept or reject a method transfer.
ICH Quality Guidelines: An Implementation Guide
Covers the Q10/Q12 lifecycle and change management principles that WHO's 2022 technology transfer update explicitly builds on, plus the quality risk management approach behind Phase 1's gap analysis.
Find it on Amazon →06Technology transfer self-check
Readiness checklist
07Where transfers fail inspection
- Skipping or rushing the gap analysis. Committing to a transfer timeline before understanding the differences between sending and receiving units is one of the most common root causes of a failed or delayed transfer.4,5
- Acceptance criteria written after the data comes in. Comparative testing criteria set retroactively to match whatever results happened to come out undermines the point of a predefined acceptance approach.
- Production transferred, method transfer forgotten. A process that moves sites without a parallel, deliberate transfer of the analytical methods testing it leaves the receiving unit unable to reliably confirm its own output.
- No closure against the original plan. A transfer report that doesn't reference back to the initial gap analysis and protocol makes it hard to demonstrate the transfer achieved what it set out to.
08Specimen quality forms
A gap analysis / transfer protocol summary and a comparative testing results record — the two documents that typically anchor a technology transfer package end to end.
Form TT-01 — Gap Analysis & Transfer Protocol Summary
Specimen only — not a controlled document. Full protocol should define detailed acceptance criteria and a complete equipment/facility comparison.
| Area compared | Gap identified? | Action required |
|---|---|---|
| Equipment / scale | ||
| Facility / utilities qualification status | ||
| Personnel training / experience | ||
| Analytical method transfer approach |
Form TT-02 — Comparative Testing Results Record
Specimen only — for recording side-by-side SU/RU results against predefined acceptance criteria.
| Sample | SU result | RU result | % difference | Pass / Fail |
|---|---|---|---|---|
These specimen forms illustrate typical content only. Your quality system's document control procedure — numbering, revision history, approval routing — takes precedence over this format.
09References
- World Health Organization. WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing. WHO Technical Report Series, No. 961, Annex 7, 2011. extranet.who.int
- World Health Organization. TRS 961, Annex 7 (full text). extranet.who.int
- World Health Organization. TRS 1044 – Annex 4: WHO Guidelines on Technology Transfer in Pharmaceutical Manufacturing. April 2022. who.int
- gmp-compliance.org. "WHO TRS1044-Annex4: Technology Transfer in Pharmaceutical Manufacturing" (full text). gmp-compliance.org
- gmp-compliance.org. "WHO: Updates on Method Transfer." gmp-compliance.org
No comments:
Post a Comment